Shunnichi Kashida
CEO
xFOREST Therapeutics
xforestx.com
Website unreachable since Oct 21, 2026
XFOREST Therapeutics utilizes RNA structure-based drug discovery to identify and develop novel therapeutics for diseases linked to genetic mutations. The company focuses on addressing the limitations of traditional drug discovery methods by providing more targeted and effective treatment options.
- Biotechnology
Updated 23 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Many diseases are linked to genetic mutations, and traditional drug discovery methods often fall short in providing targeted and effective treatment options for these conditions. Existing approaches may not adequately address the complexities of RNA structure and its role in disease pathology.
Solution
XFOREST Therapeutics employs RNA structure-based drug discovery to create innovative therapeutics for diseases caused by genetic mutations. By focusing on RNA structure, the company aims to overcome the limitations of conventional drug discovery, leading to more precise and efficacious treatments. This approach allows for the identification of novel drug targets and the development of therapies that specifically interact with RNA, modulating its function to address the underlying causes of disease. The company's technology enables the design of drugs that can selectively bind to and modify RNA structures, offering a new avenue for treating genetic disorders.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing treatments for genetic diseases, as well as patients suffering from conditions linked to genetic mutations.
Features
- RNA structure-based drug design platform
- Identification of novel drug targets through RNA analysis
- Development of therapeutics that selectively interact with RNA structures
- Modulation of RNA function to address genetic disease causes